[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-efficacy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-efficacy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100629901","eribulin-mesylate-based-therapy-in-patients-with-advanced-her2-negative-breast-cancer-previously-treated-with-adc-100629901",false,"NCT07480694","Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates","Inclusion Criteria:\n\n1. At least 18 years old;\n2. Inoperable locally advanced or metastatic breast cancer;\n3. Planning to use a single-agent or combination treatment regimen based on eribulin;\n4. HER2 negative (IHC 0,+, or ++ but ISH negative);\n5. Previously received ADC treatment at the local advanced or metastatic disease stage;\n6. Previously received chemotherapy (including ADC) for local advanced or metastatic disease no more than 2 lines, where one treatment line is defined as completing at least one cycle of chemotherapy;\n7. Eastern Cooperative Oncology Group (ECOG) performance status score (PS) 0-2;\n8. The investigators have evaluated that the patient's organ and bone marrow functions are suitable for medication use and there are no relevant contraindications;\n9. The subjects voluntarily join the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. HER2-positive tumors\n2. The hormone receptor status is unknown;\n3. Patients who have received eribulin treatment before;\n4. Those who have had other malignant tumors within the past 5 years (excluding the following situations: cured skin basal cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma; second primary cancer that has been cured and has no recurrence within 5 years; subjects who have clearly identified the origin of the metastatic lesion as being from a certain primary tumor);\n5. Mental illness or mental disorder, patients with poor compliance and inability to cooperate and describe treatment responses;\n6. Pregnant or lactating women;\n7. Other serious or uncontrollable diseases, or other conditions assessed by the researcher as not suitable for enrollment.","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","12 Months","OBSERVATIONAL","This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.",[25],"Treatment Efficacy",[27],"Eribulin Mesylate-based Therapy, Advanced HER2-negative Breast Cancer, ADC","NOT_YET_RECRUITING","2026-03-14",{"date":31,"type":32},"2026-03-18","ACTUAL",{"date":34,"type":20},"2026-03",{"date":36,"type":20},"2028-02",{"name":38,"class":39},"Fudan University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100533123","predicting-treatment-outcomes-in-refractory-constipation-through-brain-connectivity-evaluation-100533123","NCT06221722","Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation","Evaluation of Brain Connectivity Function in Predicting Therapeutic Effects in Patients With Refractory Constipation: a Multicenter, Prospective, Cohort Study","Inclusion Criteria:\n\n* 18≤ age ≤ 45 years old\n* Right-handed\n* Patients diagnosed as functional constipation according to the Rome IV criteria\n* Informed consent of patients\n\nExclusion Criteria:\n\n* Complicated with gastrointestinal organic disease or significant functional abnormalities (tuberculosis, polyps, Crohn's disease, tumors, congenital megacolon, pelvic floor muscle relaxation, abnormal colonic transit test, etc.)\n* Long-term intense exercise (continuous exercise for more than 8 hours per week, such as marathon runners or triathletes)\n* No history of chronic pain, no recent major trauma\n* Drug abuse or tobacco dependence (half a pack or more per day)\n* Combined hypothyroidism and Parkinson's disease\n* Patients with confirmed mental illness or neurological disorders who take psychotropic drugs, analgesics or hormones\n* History of abdominal surgery (appendectomy, hysterectomy, or cholecystectomy)\n* Contraindications to functional magnetic resonance imaging (claustrophobia, metal implants)\n* Pregnant or lactating women with constipation after delivery\n* Patients with other benign and malignant tumors and autoimmune diseases\n* Infectious diseases such as hepatitis B, hepatitis C, AIDS, etc.\n* Heart disease, organ failure and other chronic diseases that require long-term medication or affect the quality of life",true,"45 Years",{"count":50,"type":20},150,"The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are:\n\n* Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients\n* Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation.\n\nParticipants will receive:\n\n* Standard physiological and psychological assessments of constipation\n* BOLD-fMRI tests\n* Standard protocol and fluoxetine treatment\n\nIf there is a comparison group: Researchers will compare:\n\nRefractory group\u002FFluoxetine sensitive group to see the specific brain alterations.",[53,54,55,56,57,25,58,59],"Constipation - Functional","Refractory Constipation","Fluoxetine","fMRI","Brain Connectivity","Somatic Symptom","Mental Symptom",[56,61,62],"functional connectivity","refractory constipation","RECRUITING","2025-07-22",{"date":66,"type":32},"2025-07-24",{"date":68,"type":32},"2023-11-01",{"date":70,"type":20},"2026-09-01",{"name":72,"class":39},"Xijing Hospital of Digestive Diseases",3]